Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis
Brain · 03.10.2024 · 147 (10) · 3573-3582
DOI: 10.1093/brain/awae110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 17.04.2024. Verfasst von Jesse Huang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Hauptthemen laut MEDLINE: Multiple Sclerosis, Herpesvirus 4, Human, Epstein-Barr Virus Nuclear Antigens, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Multiple Sclerosis Society of Canada, Swedish Brain, Swedish Association of Persons with Neurological Disabilities Foundation.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) infection has been advocated as a prerequisite for developing multiple sclerosis (MS) and possibly the propagation of the disease. However, the precise mechanisms for such influences are still unclear. A large-scale study investigating the host genetics of EBV serology and related clinical manifestations, such as infectious mononucleosis (IM), may help us better understand the role of EBV in MS pathogenesis. This study evaluates the host genetic factors that influence serological response against EBV and history of IM and cross-evaluates them with MS risk and genetic susceptibility in the Swedish population. Plasma IgG antibody levels against EBV nuclear antigen-1 [EBNA-1, truncated = amino acids (aa) (325–641), peptide = aa(385–420)] and viral capsid antigen p18 (VCAp18) were measured using bead-based multiplex serology for 8744 MS cases and 7229 population-matched control subjects. The MS risk association for high/low EBV antibody levels and history of IM was compared to relevant clinical measures along with sex, age at sampling, and associated HLA allele variants. Genome-wide and HLA allele association analyses were also performed to identify genetic risk factors for EBV antibody response and IM history. Higher antibody levels against VCAp18 [odds ratio (OR) = 1.74, 95% confidence interval (CI) = 1.60–1.88] and EBNA-1, particularly the peptide (OR = 3.13, 95% CI = 2.93–3.35), were associated with an increased risk for MS. The risk increased with higher anti-EBNA-1 IgG levels up to 12× the reference risk. We also identified several independent HLA haplotypes associated with EBV serology overlapping with known MS risk alleles (e.g. DRB1*15:01). Although there were several candidates, no variants outside the HLA region reached genome-wide significance. Cumulative HLA risk for anti-EBNA-1 IgG levels, particularly the peptide fragment, was strongly associated with MS. In contrast, the genetic risk for high anti-VCAp18 IgG levels was not as strongly associated with MS risk. IM history was not associated with class II HLA genes but negatively associated with A*02:01, which is protective against MS. Our findings emphasize that the risk association between anti-EBNA-1 IgG levels and MS may be partly due to overlapping HLA associations. Additionally, the increasing MS risk with increasing anti-EBNA-1 levels would be consistent with a pathogenic role of the EBNA-1 immune response, perhaps through molecular mimicry. Given that high anti-EBNA-1 antibodies may reflect a poorly controlled T-cell defence against the virus, our findings would be consistent with DRB1*15:01 being a poor class II antigen in the immune defence against EBV. Last, the difference in genetic control of IM supports the independent roles of EBNA-1 and IM in MS susceptibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
- Centrum for Molecular Medicine, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
- Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, SE 751 23 Uppsala, Sweden.
- Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), DE-69120 Heidelberg, Germany.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
- Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
ORCID-Profile: Katarina Tengvall, Julia Butt, Ingemar Ernberg, Ali Manouchehrinia, Ingrid Kockum
Förderung
- Multiple Sclerosis Society of Canada
- Swedish Brain
- Swedish Association of Persons with Neurological Disabilities Foundation
- Swedish research council
- Horizon 2020 MultipleMS
- KID
- Karolinska Institutet
- Swedish Research Council for Health
Zitieren
APA
Huang, J., Tengvall, K., Lima, I. B., Hedström, A. K., Butt, J., Brenner, N., Gyllenberg, A., Stridh, P., Khademi, M., Ernberg, I., Al Nimer, F., Manouchehrinia, A., Hillert, J., Alfredsson, L., Andersen, O., Sundström, P., Waterboer, T., Olsson, T., & Kockum, I. (2024). Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis. Brain, 147(10), 3573-3582. https://doi.org/10.1093/brain/awae110
Vancouver
Huang J, Tengvall K, Lima IB, Hedström AK, Butt J, Brenner N, et al. Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis. Brain. 2024;147(10):3573-3582. doi:10.1093/brain/awae110
BibTeX
@article{Huang2024,
author = {Huang, Jesse and Tengvall, Katarina and Lima, Izaura Bomfim and Hedström, Anna Karin and Butt, Julia and Brenner, Nicole and Gyllenberg, Alexandra and Stridh, Pernilla and Khademi, Mohsen and Ernberg, Ingemar and Al Nimer, Faiez and Manouchehrinia, Ali and Hillert, Jan and Alfredsson, Lars and Andersen, Oluf and Sundström, Peter and Waterboer, Tim and Olsson, Tomas and Kockum, Ingrid},
title = {Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis},
journal = {Brain},
year = {2024},
volume = {147},
number = {10},
pages = {3573--3582},
doi = {10.1093/brain/awae110}
}
EUVIMED